TLX Telix Pharmaceuticals Limited
Company Analysis
Latest News
π΄ Telix Pharmaceuticals is trading 10% down today after Q3 revenue fell 1% sequentially
Telix Pharmaceuticals is trading at $10.04, down 10.08%, after its Q3 update showed group revenue fell 1% sequentially. - Group revenue was US$245 million, up...
Telix Posts Strong Year-Over-Year Growth but a Flat Quarter β Is the Imaging Pioneer Hitting a Revenue Ceiling or Just Catching Its Breath?
Shares of Telix Pharmaceuticals tumbled nearly 10% to $10.05 after the Australian radiopharmaceutical company's Q3 update revealed a sequential stumble beneath...
π΄ Telix Pharmaceuticals is trading 10% down today amid apparent profit-taking on already-priced-in positive news
Telix Pharmaceuticals is trading at $10.05 (-9.95%) following Q3 update-related selling; a report said investors were spooked, though the decline mostly...
π΄ Telix Pharmaceuticals is trading 6% down in pre-market β catalyst unclear
Telix Pharmaceuticals is trading 5.91% down at $10.50 in pre-market following its Q3 2026 update; reporting does not establish the update as the cause of the...
π΄ Telix Pharmaceuticals is trading 7.35% down in after-hours trading; cause remains unclear
Telix Pharmaceuticals is trading at $10.34, down 7.35% in after-hours trading; available reporting does not establish a cause for the decline. - Its Q3 2026...
π’ Telix Pharmaceuticals is trading 4.14% up today amid 2.12% healthcare-sector gains
Telix Pharmaceuticals is trading at $11.19, up +4.14%, with healthcare-sector strength the clearest available context. - Healthcare is up 2.12%, as investors...
π’ Telix Pharmaceuticals is trading 5.4% up in pre-market with no confirmed catalyst
Telix Pharmaceuticals is trading at $11.32, up 5.39% pre-market; no confirmed catalyst directly explains the move. - On October 19, 2026, Telix announced a...
Telix Launches Pixclara Commercially in U.S. After FDA Approval
Telix Pharmaceuticals has begun the U.S. commercial rollout of Pixclara, its newly FDA-approved brain cancer imaging agent. The first commercial doses were...
π’ Telix Pharmaceuticals is trading 4.93% up in after-hours trading despite concerns over proposed ITM acquisition dilution
Telix Pharmaceuticals is trading at $11.83, up 4.93%, after regular-session losses tied to investor concerns about its proposed ITM acquisition. - The US$1.65...
π΄ Telix Pharmaceuticals is trading 5% down today as dilution concerns weigh on ITM deal
Telix Pharmaceuticals is trading at $11.36, down 5%, as investors reassess dilution from its proposed US$1.65 billion acquisition of ITM Isotope Technologies...
π’ Telix Pharmaceuticals is trading 6.72% up today after announcing proposed US$1.65 billion acquisition of ITM
Telix Pharmaceuticals is trading 6.72% up now at $12.07 after announcing its proposed US$1.65 billion acquisition of ITM Isotope Technologies Munich. -...
π’ Telix Pharmaceuticals is trading 4.77% up in pre-market after announcing US$1.65 billion ITM acquisition
Telix Pharmaceuticals is trading 4.77% up at $11.85 after announcing its US$1.65 billion acquisition of ITM Isotope Technologies Munich. β’ The transaction...
π΄ Telix Pharmaceuticals is trading 11.8% down today after announcing US$1.65 billion acquisition of ITM
Telix Pharmaceuticals is trading 11.8% down at $11.23 after announcing a US$1.65 billion acquisition of ITM Isotope Technologies Munich. - The transaction...
Telix Bets $1.65 Billion on a Radioactive Drug Supplier β But Will Shareholders Pay the Price for an FDA-Rejected Asset?
Shares plunged 11% to $11.21 as Telix Pharmaceuticals unveiled its largest-ever deal: a US$1.65 billion acquisition of Germany's ITM Isotope Technologies...
π΄ Telix Pharmaceuticals is trading 11% down in pre-market after announcing US$1.65 billion acquisition of ITM
Telix Pharmaceuticals is trading 10.96% down now at $11.21 in pre-market after announcing a US$1.65 billion acquisition of ITM Isotope Technologies Munich on...
π΄ Telix Pharmaceuticals is trading 4.7% down in pre-market after announcing US$1.65 billion ITM acquisition
Telix Pharmaceuticals is trading 4.7% down now at $12.00 after announcing a strategic agreement to acquire ITM Isotope Technologies Munich for US$1.65...
π’ Telix Pharmaceuticals is trading 8% up today as markets recover after Fed's September 16 decision
Telix Pharmaceuticals is trading 7.51% up now at $12.58 as U.S. equities recover following the Federal Reserveβs September 16 rate decision. - The S&P 500 and...
π’ Telix Pharmaceuticals is trading 5.49% up in pre-market as Nasdaq and S&P 500 rebound
Telix Pharmaceuticals is trading 5.49% up in pre-market at $12.48 after a broader pre-market recovery lifted major U.S. indexes. - Nasdaq Composite rose...
π΄ Telix Pharmaceuticals is trading 7.13% down today on profit-taking after Pixclara FDA approval
Telix Pharmaceuticals is trading 7.13% down at $11.91, apparently reflecting profit-taking after the September 14 FDA approval of Pixclara. - Shares rose...
π΄ Telix Pharmaceuticals is trading 4.1% down in pre-market β possible profit-taking after Pixclara approval
Telix Pharmaceuticals is trading 4.13% down at $12.30 in pre-market, possibly reflecting profit-taking after its approval-driven rally. - It rose 8.91% to...